Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Files An 8-K Other Events
ITEM8.01
| Other Events. |
On May1, 2017, Intra-Cellular Therapies, Inc. (the Company)
provided an update on its clinical program of its lead drug
candidate, lumateperone (ITI-007), for the treatment of
schizophrenia.
The Companys press release providing an update on its clinical
program of lumateperone for the treatment of schizophrenia is
filed as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.
| ITEM9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
|
Exhibit Number |
Description |
|
| 99.1 | Press release dated May1, 2017 |
About Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company’s pipeline includes approximately two product candidates in clinical development and two product candidates in advanced pre-clinical testing. Its platform includes ITI-007 platform and phosphodiesterase (PDE) Inhibitor Platform. It is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances associated with dementia, autism and other CNS diseases. Its ITI-007 platform also includes long acting injectable (LAI) program, and IC200131 program for mood and other disorders. Its PDE Inhibitor Platform includes PDE1 program and PDE2 and PDE9 programs. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Recent Trading Information
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) closed its last trading session up +0.37 at 13.82 with 529,187 shares trading hands.
